Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
ET
- ET
WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs. - Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
- KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others.
- Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a.